Phase 2 N=29 Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
Heart Failure
Primary: Telemetry — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Trial of Oral Glutamine on Mitochondrial Function in CKD
Cardiovascular Disease · Sarcopenia · Endothelial Dysfunction
Primary: Muscle Mitochondrial Function — 0.88; 0.90 mM ATP/s — p=0.15
Phase 2 N=56 Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty
Pain, Postoperative · Mammaplasty
Primary: Initial Visual Analog Scale (VAS) Pain Scores — 8.3; 7.4 score on a scale
Phase 2 N=88 Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: PSA Progression-free Survival — 20.8; 16.5 Months — p=0.83
Phase 2 N=54 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: Number of Participants With Morphological Complete Response Rate — 27; 20 Participants
Phase 2 N=121 A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Efficacy Measured by Time to Stand Test (TTSTAND) Velocity in Rises/Second Change From Baseline — -.007; 0.054 Rises/Seconds
Phase 2 N=69 An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Patients With Complete Renal Response (CRR) and Without Any Renal Flares — 51.83; 48.15; 59.49; 57.51 Percentage of participants — p=0.7957
Phase 2 N=493 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Over Time — 87.7; 73.4; 77.8; 89.0 percentage of participants
Phase 2 N=11 Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
Breast Cancer
Primary: Maximum Change in LVEF at 3 Months — 1; -5 change in percent ejection fraction
Phase 2 N=32 Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) — 6.6 months
Phase 2 N=252 Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
Malaria
Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants
Phase 2 N=21 NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Severe Aplastic Anemia · Aplastic Anemia · Bone Marrow Failure
Primary: Overall Survival and Engraftment at One Year — 19 Participants
Phase 2 N=32 Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
Severe Aplastic Anemia
Primary: Percentage of Participants With Overall Survival (OS) — 80.6 percentage of participants
Phase 2 N=42 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
B-cell Lymphoma
Primary: Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators — 86 percentage of participants
Phase 2 N=27 Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
Glomerulonephritis
Primary: Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) — 0.55 ratio — p=0.0003